Iovance Biotherapeutics, Inc. (2LB.F)
Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Dr. Frederick G. Vogt Esq., J.D., Ph.D. | Interim CEO, President, General Counsel, Corporate Secretary & Director | 862.79k | -- | 1974 |
| Mr. Jean-Marc Bellemin M.B.A. | CFO, Principal Accounting Officer & Treasurer | 604.99k | -- | 1972 |
| Dr. Igor P. Bilinsky Ph.D. | Chief Operating Officer | 604.99k | -- | 1973 |
| Dr. Friedrich Graf Finckenstein M.D. | Chief Medical Officer | 670.36k | -- | 1967 |
| Dr. Raj K. Puri M.D., Ph.D. | Chief Regulatory Officer | 731.16k | -- | 1956 |
| Ms. Sara Pellegrino | Senior Vice President of Investor Relations & Corporate Communications | -- | -- | -- |
| Ms. Tracy Winton | Executive Vice President of Human Resources | -- | -- | -- |
| Mr. Howard B. Johnson M.B.A. | Chief Business Officer | -- | -- | 1960 |
| Mr. Brian Shew M.B.A. | Senior VP & Head of Digital and Information Technology | -- | -- | -- |
| Mr. Kevin Smyth | Executive Vice President of Quality | -- | -- | -- |
Iovance Biotherapeutics, Inc.
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 838
Description
Iovance Biotherapeutics, Inc., a commercial-stage biopharmaceutical company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States. The company offers Amtagvi, a tumor-derived autologous T cell immunotherapy used to treat adult patients with unresectable or metastatic melanoma; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic melanoma and metastatic renal cell carcinoma. It develops lifileucel for treatment of melanoma, cervical cancer, non-small cell lung cancer (NSCLC), endometrial cancer, and head and neck squamous cell carcinoma; IOV-2001 to treat chronic lymphocytic leukemia and small lymphocytic lymphoma; IOV-4001 for the treatment of melanoma and NSCLC; and IOV-3001, an antibody cytokine engrafted protein for use in the TIL therapy treatment regimen. The company has collaborations and licensing agreements with WuXi Advanced Therapies, Inc.; National Institutes of Health; the National Cancer Institute; H. Lee Moffitt Cancer Center; The University of Texas M.D. Anderson Cancer Center; Cellectis S.A.; Novartis Pharma AG; and Boehringer Ingelheim Biopharmaceuticals GmbH. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was incorporated in 2007 and is headquartered in San Carlos, California.
Corporate Governance
Upcoming Events
August 6, 2025 at 8:00 PM UTC - August 11, 2025 at 8:00 PM UTC
Iovance Biotherapeutics, Inc. Earnings Date
Recent Events
Recent Events Information Not Available